Geke A P Hospers Selected Research

Chemoradiotherapy

4/2022	The Multimodal Management of Locally Advanced Rectal Cancer: Making Sense of the New Data.
1/2022	Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer - The RAPIDO trial.
9/2021	Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible.
7/2021	Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis.
1/2021	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
1/2021	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
10/2020	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
1/2020	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.
9/2018	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
1/2018	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Geke A P Hospers Research Topics

Disease

42	Neoplasms (Cancer) 12/2022 - 01/2002
37	Melanoma (Melanoma, Malignant) 12/2022 - 01/2003
20	Breast Neoplasms (Breast Cancer) 11/2022 - 11/2004
13	Neoplasm Metastasis (Metastasis) 11/2022 - 07/2011
12	Rectal Neoplasms (Rectal Cancer) 04/2022 - 03/2004
10	Esophageal Neoplasms (Esophageal Cancer) 07/2021 - 06/2013
8	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2018
5	Adenocarcinoma 01/2021 - 06/2013
5	Stomach Neoplasms (Stomach Cancer) 09/2018 - 06/2010
2	Carcinoma (Carcinomatosis) 04/2017 - 01/2005
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2015 - 06/2013
2	Colorectal Neoplasms (Colorectal Cancer) 06/2013 - 11/2011
2	Colonic Neoplasms (Colon Cancer) 06/2013 - 05/2006
2	Vascular Diseases (Vascular Disease) 01/2007 - 02/2006
2	Coronary Artery Disease (Coronary Atherosclerosis) 05/2005 - 09/2004
1	Lymphatic Metastasis 01/2022
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2022
1	Hepatitis 04/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Immune System Diseases (Immune Disorders) 01/2021
1	Disease Progression 07/2019
1	Systemic Vasculitis 01/2018
1	Colitis 01/2018

Drug/Important Bio-Agent (IBA)

13	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
12	Estrogen ReceptorsIBA 11/2022 - 02/2012
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2011 - 01/2003
7	16-fluoroestradiolIBA 11/2022 - 01/2018
7	IpilimumabIBA 01/2022 - 11/2013
7	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2020 - 05/2014
6	Estradiol (Delestrogen)FDA LinkGeneric 11/2022 - 10/2015
6	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2010
6	Pharmaceutical PreparationsIBA 01/2019 - 11/2004
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2022 - 01/2021
5	Capecitabine (Xeloda)FDA Link 01/2020 - 01/2005
5	VemurafenibIBA 01/2018 - 05/2013
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 09/2018 - 01/2005
4	Proteins (Proteins, Gene)FDA Link 01/2017 - 01/2005
3	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 12/2017
3	human ERBB2 proteinIBA 10/2020 - 12/2017
3	Carboplatin (JM8)FDA LinkGeneric 09/2018 - 08/2014
3	Paclitaxel (Taxol)FDA LinkGeneric 09/2018 - 08/2014
2	NivolumabIBA 01/2022 - 01/2022
2	Trastuzumab (Herceptin)FDA Link 10/2020 - 01/2020
2	Formaldehyde (Formol)FDA Link 01/2020 - 01/2018
2	Biological ProductsIBA 01/2019 - 01/2018
2	Glucose (Dextrose)FDA LinkGeneric 11/2018 - 01/2011
2	ParaffinIBA 01/2018 - 01/2015
2	GenisteinIBA 11/2017 - 04/2017
2	2- fluoro- 6- (6- hydroxynaphthalen- 2- yl)pyridin- 3- olIBA 11/2017 - 04/2017
2	Estrogens (Estrogen)FDA Link 04/2017 - 11/2016
2	Proto-Oncogene Proteins B-rafIBA 01/2017 - 04/2014
2	Phosphotransferases (Kinase)IBA 01/2017 - 01/2011
2	LigandsIBA 01/2015 - 11/2004
2	Bevacizumab (Avastin)FDA Link 01/2015 - 07/2011
2	Fluorouracil (Carac)FDA LinkGeneric 05/2006 - 01/2005
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2005 - 01/2003
1	Trinitrotoluene (TNT)IBA 01/2022
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 12/2021
1	Interleukin-2 (IL2)IBA 12/2021
1	antineoplaston A10 (A 10)IBA 09/2021
1	Programmed Cell Death 1 ReceptorIBA 04/2021
1	Dihydrotestosterone (Androstanolone)IBA 01/2021
1	AntibodiesIBA 01/2021
1	bicalutamide (Casodex)FDA LinkGeneric 01/2021
1	BMS-986192IBA 12/2020
1	AZD 6244IBA 12/2020
1	Lactate DehydrogenasesIBA 11/2020
1	GRB7 Adaptor ProteinIBA 10/2020
1	ErbB Receptors (EGF Receptor)IBA 10/2020
1	pertuzumabIBA 10/2020
1	Cell-Free Nucleic AcidsIBA 01/2020
1	palbociclibIBA 01/2020
1	Circulating Tumor DNAIBA 01/2020
1	Letrozole (Femara)FDA LinkGeneric 01/2020
1	Deoxyglucose (2 Deoxy D glucose)IBA 01/2020
1	FluoridesIBA 01/2020
1	SodiumIBA 01/2020
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2020
1	ElementsIBA 11/2019
1	pembrolizumabIBA 07/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2018
1	Docetaxel (Taxotere)FDA Link 09/2018
1	HLA-DR Antigens (HLA-DR)IBA 01/2018
1	AndrogensIBA 12/2017
1	MitogensIBA 01/2017

Therapy/Procedure

32	Therapeutics 03/2022 - 08/2004
16	Radiotherapy 04/2022 - 03/2004
15	Chemoradiotherapy 04/2022 - 06/2013
13	Neoadjuvant Therapy 01/2022 - 11/2013
10	Drug Therapy (Chemotherapy) 04/2022 - 01/2003
3	Adjuvant Chemotherapy 01/2021 - 06/2013
2	Adjuvant Chemoradiotherapy 09/2018 - 01/2005
2	Esophagectomy 07/2016 - 02/2014
1	Combined Modality Therapy 04/2022
1	Duration of Therapy 01/2022
1	Lymph Node Excision (Lymph Node Dissection) 01/2022
1	Re-Irradiation 09/2021
1	Brachytherapy 01/2021
1	Immunotherapy 05/2020